Evotec SE 6-K, filed Nov 5, 2026

Evotec SE (EVO)

6-K 2026-11-05 For: 2026-11-05

Added on November 05, 2026

About this 6-K

Evotec SE filed this 6-K on November 5, 2026.

Evotec SE reported nine-month 2026 revenue of €465.0 million, down 13.1% from €535.1 million, while reaffirming full-year 2026 revenue guidance of €570 to €610 million and adjusted Group EBITDA of -€105 to -€70 million. Horizon transformation is ahead of plan. AI summary

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →

Exhibit	Description of Exhibit
99.1	Interim Statement First Nine Months 2026

99.2	Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals

	Evotec SE

	By:	/s/ Claire Hinshelwood
		Name: Claire Hinshelwood
		Title: Chief Financial Officer

4	D&PD LEADING COMMERCIAL INDICATORS SHOW CONTINUED IMPROVEMENT

4	JUST – EVOTEC BIOLOGICS (“JEB”) Q3 PERFORMANCE AFFECTED BY PARTIAL MILESTONE ACHIEVEMENT; FULL-YEAR OUTLOOK IMPACTED BY MILESTONE TIMING, PROJECT SHIFTS AND DEFERRALS

4	HORIZON TRANSFORMATION WELL ON TRACK

4	EVOTEC EXPANDS ITS STRATEGIC RESEARCH COLLABORATION NETWORK IN IMMUNOLOGY AND ONCOLOGY; JEB ADVANCES ORTHOPOXVIRUS ANTIBODIES INTO PHASE 1 CLINICAL STUDIES

4	NINE-MONTH 2026 RESULTS ABOVE MARKET EXPECTATIONS; FULL-YEAR 2026 GUIDANCE REAFFIRMED

4	Group revenue decreased by 13.1% to € 465.0 m (9M 2025: € 535.1 m) while remaining well above expectations implied by Q3 consensus estimates and consistent with FY 2026 guidance range

4	Total D&PD revenue decreased by 11.2% to € 348.2 m (9M 2025: € 392.1 m), mainly attributable to lower sales conversion across all business areas, reflecting ongoing timing-related impacts from commercial initiatives

4	JEB revenue decreased by 18.3% to € 117.1 m (9M 2025: € 143.4 m), primarily driven by the USD 25 m Sandoz license sale recognized in Q1 2025, the timing of program-related activities and customer project progression

4	Horizon is progressing slightly ahead of schedule, supporting the delivery of the previously communicated plan to realize 20–30% of the € 75 m run-rate savings from 2027 into 2026.

4	Adjusted Group EBITDA totalled € (44.3) m (9M 2025: € (16.9) m) primarily impacted by lower revenue, partly offset by lower R&D expenditure and other operating cost effects, and remained significantly above expectations implied by Q3 consensus estimates and fully in line with the FY 2026 guidance range.

	9M 2026												9M 2025
in k€	D&PD			JEB			Intersegment eliminations			Evotec Group			D&PD			JEB			Intersegment eliminations			Evotec Group
Revenue¹		347,955			117,094			—			465,049			391,861			143,239			—			535,100
Intersegment revenue		287			—			(287	)		—			195			126			(321	)		—
Cost of revenue²		(320,426	)		(128,262	)		287			(448,402	)		(338,876	)		(139,432	)		321			(477,987	)
Gross profit (loss)		27,815			(11,168	)		—			16,647			53,180			3,933			—			57,114
Gross margin in %		8.0			(9.5	)		—			3.6			13.6			2.7			—			10.7

Research and development costs²		(29,682	)		—			—			(29,682	)		(42,185	)		(71	)		—			(42,256	)
Selling, general and administrative expenses²		(97,155	)		(24,707	)		—			(121,862	)		(115,815	)		(22,585	)		—			(138,400	)
Other operating income		29,553			1,603			—			31,156			38,516			2,856			—			41,371
Other operating expenses		(53,987	)		(5,132	)		—			(59,119	)		(7,224	)		(3,631	)		—			(10,855	)
Reorganization costs		(91,922	)		—			—			(91,922	)		741			—			—			741
Operating income (loss)		(215,377	)		(39,405	)		—			(254,781	)		(72,786	)		(19,499	)		—			(92,284	)

Adjusted EBITDA		(25,470	)		(18,846	)		—			(44,316	)		(18,826	)		1,940			—			(16,886	)

4	August 6: Evotec and Odyssey Therapeutics enter an R&D collaboration in complex autoimmune and inflammatory diseases enabled by Evotec’s deep disease biology expertise and proprietary AI-enabled technologies

4	September 2: Evotec and Plectonic enter a research collaboration to explore new generation of T-cell-engaging approaches for solid tumors

4	September 9: Just – Evotec Biologics advances U.S. Department of War antibodies against orthopoxvirus into Phase 1 clinical studies

4	July 13: Evotec announces preliminary second quarter and first half 2026 results and updates full-year 2026 outlook

4	September 29: Evotec reports that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective September 30, 2026

4	October 13: Evotec announces preliminary nine-month 2026 results above market expectations, reaffirms full-year 2026 guidance

4	October 15: Evotec appoints Dr. Joanna Holbrook as Chief Scientific Officer and member of the Management Board effective November 1, 2026

4	Group revenues expected in the range of € 570 – 610 m (€ 595 – 635 m CER; 2025: € 788.4 m)

4	Adjusted Group EBITDA is expected to reach € (70) – (105) m (€ (60) – (90) m CER; 2025: € 41.1 m)

in k€ except share and per share data	9M 2026			9M 2025
Revenue		465,049			535,100
Cost of revenue¹		(448,402	)		(477,987	)
Gross profit (loss)		16,647			57,114

Operating income (expenses)
Research and development costs¹		(29,682	)		(42,256	)
Selling, general and administrative expenses¹		(121,862	)		(138,400	)
Other operating income		31,156			41,371
Other operating expenses		(59,119	)		(10,855	)
Reorganization costs		(91,922	)		741
Total operating income (expenses)		(271,429	)		(149,398	)
Operating income (loss)		(254,781	)		(92,284	)

Non-operating income (expenses)
Realized gain (loss) on investments and financial instruments revaluation		68,459			1,739
Share of profit (loss) and revaluation of at-equity investments		(1,525	)		(736	)
Other financial income		4,683			3,264
Other financial expenses		(9,462	)		(10,685	)
Other non-operating income (expenses)		303			(17,527	)
Net income (loss) before taxes		(192,324	)		(116,230	)
Income taxes		(3,005	)		(1,911	)
Net income (loss)		(195,329	)		(118,141	)

Weighted average shares outstanding		177,653,851			177,598,303
Net result per share (basic)		(1.10	)		(0.67	)
Net result per share (diluted)		(1.10	)		(0.67	)

in k€	09/30/2026		12/31/2025
ASSETS
Current assets:
Cash and cash equivalents		299,012		418,517
Investments		101,925		57,873
Trade and other receivables		108,556		135,963
Contract assets		28,683		28,295
Inventories		37,710		29,317
Current tax assets		34,033		38,453
Other current financial assets including derivatives		17,541		20,217
Prepaid expenses and other current assets		35,803		30,480
Assets classified as held for sale		—		3,830
Total current assets		663,263		762,945

Non-current assets:
Non-current investments and other non-current financial assets		36,107		48,004
Investments in associates and joint ventures		3,107		4,629
Property, plant and equipment		444,536		554,626
Intangible assets and goodwill		307,234		303,936
Deferred tax assets		113		2,949
Non-current tax assets		49,247		36,349
Other non-current assets		1,364		507
Total non-current assets		841,707		951,000
Total assets		1,504,970		1,713,945

·	*Financial performance:* Q3 and nine-month Group revenue of €164.9 m and €465.0 m, respectively (Q3: €164.2 m, 9M: €477.4 m at CER); adj. Group EBITDA of -€1.6 m and -€44.3 m, respectively (Q3: -€1.7 m, 9M: -€39.1 m at CER)

·	*Robust commercial momentum:* Net sales in D&PD base business increased 24% vs. 9M 2025 accompanied by continued positive development across key commercial indicators.*

·	*FY 2026 guidance reaffirmed:* Expected Group revenue of €570 to €610 m (€595 to €635 m CER) and adj. Group EBITDA of -€105 to -€70 m (-€90 to -€60 m CER).

·	*2030 framework further detailed:* Around €1 billion in Group revenue by 2030 with further upside potential; adjusted EBITDA margin of 20% at YE 2028 and above 20% at YE 2030.

·	*Continued progress across differentiated platforms:* Evotec confirms selection by Vertex Pharmaceuticals for commercial manufacturing of povetacicept; advancement of orthopoxvirus antibody program into Phase 1 in collaboration with DoW; new collaborations with Plectonic and Odyssey Therapeutics broaden partnered innovation activities.

·	*Horizon transformation ahead of plan:* More than 20% of €75 million annual run-rate savings target delivered by September, already within 20-30% contribution planned for full-year 2026; workforce and footprint measures on track.

·	*Leadership Update:* Dr. Joanna Holbrook appointed Chief Scientific Officer, strengthening Evotec’s focus on scientific excellence, platform differentiation and partnered innovation.

·	*Investor and analyst webcast and conference call today*: 2 p.m. CET / 1 p.m. GMT / 8 a.m. EST; registration and webcast details below.

	·	Vertex Pharmaceuticals – Commercial Manufacturing of Povetacicept: Evotec confirms that Just – Evotec Biologics has been selected by Vertex Pharmaceuticals for commercial manufacturing of povetacicept at its J.POD® Redmond facility. The agreement marks an important step in the evolution of JEB’s continuous manufacturing platform toward commercial readiness. Evotec is highly confident in its ability to fulfill its commercial manufacturing and supply commitments to Vertex.

	·	DoW Orthopoxvirus Program – JST-018 Phase 1 Initiated: In September 2026, Evotec announced the initiation of a Phase 1 clinical trial evaluating JST-018, an investigational antibody cocktail developed by Just – Evotec Biologics under the U.S. Department of War’s Accelerated Antibodies Program. Just – Evotec Biologics advanced the program from antibody sequence selection through preclinical development, process development, regulatory submission and cGMP manufacture of clinical trial materials.

	·	Plectonic Research Collaboration – Novel Immunotherapy Approaches: In September 2026, Evotec and Plectonic entered a research collaboration combining Evotec’s BiTco platform with Plectonic’s LOGIBODY® technology to explore new T-cell-engaging approaches for solid tumors. The collaboration will generate preclinical proof-of-concept data to evaluate whether the combined technologies can improve the precision and potency of these approaches.

	·	Odyssey Therapeutics Research Collaboration – AI-Enabled Drug Discovery: In August 2026, Evotec entered an R&D collaboration combining Odyssey’s expertise in autoimmune and inflammatory diseases with Evotec’s AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries. Evotec is eligible to receive milestone payments based on the successful delivery of validated starting points for drug discovery across multiple targets.

	Three months ended 30 September 2026									Three months ended 30 September 2025
(in € thousands)	D&PD			JEB			Evotec Group			D&PD			JEB			Evotec Group
Revenue		120,086			44,840			164,926			122,892			40,994			163,887
Intersegment revenue		81			—			—			166			103			—
Costs of revenue		(102,460	)		(42,752	)		(145,130	)		(110,909	)		(46,495	)		(157,135	)
Gross profit		17,708			2,088			19,796			12,150			(5,397	)		6,752
Gross margin		14.7	%		4.7	%		12.0	%		9.9	%		(13.1	)%		4.1	%
R&D expenses		(9,344	)		—			(9,344	)		(12,839	)		(9	)		(12,848	)
SG&A expenses		(30,659	)		(8,125	)		(38,784	)		(38,036	)		(6,954	)		(44,990	)
Other operating income		8,587			540			9,127			10,630			1,099			11,730
Other operating expense		(4,323	)		(3,586	)		(7,909	)		(2,157	)		(3,097	)		(5,254	)
Reorganization costs		7,003			—			7,003			108			—			108
Operating income (loss)		(11,029	)		(9,083	)		(20,112	)		(30,145	)		(14,357	)		(44,502	)
Adjusted EBITDA		(1,032	)		(600	)		(1,632	)		(9,498	)		(5,538	)		(15,036	)

in k€	9M 2026			9M 2025
Cash flows from operating activities:
Net income (loss)		(195,329	)		(118,141	)
Adjustments to reconcile net income to net cash used in operating activities¹		107,215			112,410
Change in assets and liabilities		(66,902	)		(67,077	)
Net cash provided by (used in) operating activities		(155,016	)		(72,809	)

Cash flows from investing activities:
Interest received		5,964			3,269
Purchase of property, plant and equipment		(19,162	)		(57,846	)
Proceeds from sale of property, plant and equipment		36			25
Purchase of intangible assets and additions to capitalized development expenditures		(10,649	)		(9,256	)
Investments to acquire associated companies, other non-current investments and convertibles		(2,390	)		(10,360	)
Proceeds from the disposal of associated companies, other non-current investments and convertibles, net of transaction costs		89,287			(3,764	)
Purchase of current investments		(70,054	)		(2,988	)
Proceeds from sale of current investments		26,056			29,472
Dividends received		—			1,053
Proceeds from (payments due to) the disposal of subsidiaries		(4,282	)		(396	)
Net cash provided by (used in) investing activities		14,807			(50,791	)

Cash flows from financing activities:
Interest paid		(3,120	)		(4,638	)
Proceeds from convertible bonds and other loans²		112,931			42,596
Proceeds from exercise of share options		131			218
Repayment of loans		(66,674	)		(13,039	)
Repayment of lease liabilities		(20,240	)		(16,538	)
Net cash provided by (used in) financing activities		23,028			8,599

Net increase (decrease) in Cash and cash equivalents		(117,181	)		(115,001	)
Effects of revaluation and of movements in exchange rates on cash held		(2,323	)		(12,113	)
Cash and cash equivalents at beginning of the year		418,517			306,387
Cash and cash equivalents at end of the period³		299,012			179,272

in k€	09/30/2026			12/31/2025
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current financial liabilities		64,607			104,720
Trade and other payables		48,578			64,763
Contract liabilities		60,369			104,849
Deferred income		3,714			3,220
Provisions		74,255			58,543
Current income tax liabilities		8,710			10,578
Other current liabilities		25,408			21,401
Total current liabilities		285,641			368,074

Non-current liabilities:
Non-current financial liabilities		417,207			344,008
Deferred tax liabilities		11,992			14,735
Provisions		27,378			18,035
Contract liabilities		114,746			145,324
Deferred income		6,346			8,350
Other non-current liabilities		—			1,715
Total non-current liabilities		577,668			532,167

Stockholders’ equity:
Share capital		177,910			177,779
Treasury shares, at cost		(531	)		(1,548	)
Additional paid-in capital		1,470,677			1,458,466
Retained earnings		(971,215	)		(775,887	)
Accumulated other comprehensive income		(35,179	)		(45,106	)
Total stockholders' equity		641,661			813,704
Total liabilities and stockholders’ equity		1,504,970			1,713,945

in k€	9M 2026			9M 2025
Operating income (loss)		(254,781	)		(92,284	)
Depreciation of tangible assets		64,614			69,860
Amortization of intangible assets		5,523			5,811
Impairment of tangible assets¹		42,330			—
External cyber-related costs, net of reimbursements		—			(6,203	)
Reorganization costs		91,922			(741	)
One-off arbitration costs		—			3,785
(Income) / Expenses related to the disposal of Just - Evotec Biologics EU SAS		3,202			2,885
(Income) / Expenses related to the disposal of associate companies		(254	)		—
Other non-recurring costs		3,128			—
Adjusted EBITDA		(44,316	)		(16,886	)

	Nine months ended 30 September 2026									Nine months ended 30 September 2025
(in € thousands)	D&PD			JEB			Evotec Group			D&PD			JEB			Evotec Group
Revenue		347,955			117,094			465,049			391,861			143,239			535,100
Intersegment revenue		287			—			—			195			126			—
Costs of revenue		(320,426	)		(128,262	)		(448,402	)		(338,876	)		(139,432	)		(477,987	)
Gross profit		27,815			(11,168	)		16,647			53,180			3,933			57,114
Gross margin in %		8.0	%		(9.5	)%		3.6	%		13.6	%		2.7	%		10.7	%
R&D expenses		(29,682	)		—			(29,682	)		(42,185	)		(71	)		(42,256	)
SG&A expenses		(97,155	)		(24,707	)		(121,862	)		(115,815	)		(22,585	)		(138,400	)
Other operating income		29,553			1,603			31,156			38,516			2,856			41,371
Other operating expense		(53,987	)		(5,132	)		(59,119	)		(7,224	)		(3,631	)		(10,855	)
Reorganization costs		(91,922	)		—			(91,922	)		741			—			741
Operating income (loss)		(215,377	)		(39,405	)		(254,781	)		(72,786	)		(19,499	)		(92,284	)
Adjusted EBITDA		(25,470	)		(18,846	)		(44,316	)		(18,826	)		1,940			(16,886	)